Covered recipient · General Payments record
JENNIFER LYN CULTRERA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,127.72
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,127.72 | 103 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JENNIFER LYN CULTRERA
NPI 1316041064 · CMS profile ID 195865
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
LADY LAKE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1316041064?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JENNIFER LYN CULTRERA, NPI 1316041064, CMS profile ID 195865. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316041064?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JENNIFER LYN CULTRERA, NPI 1316041064, CMS profile ID 195865. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316041064?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JENNIFER LYN CULTRERA, NPI 1316041064, CMS profile ID 195865, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316041064?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $2,127.72 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–103 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eisai Inc. | $18.40 | 01/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023314711 | CMS |
| Daiichi Sankyo Inc. | $22.76 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006378731 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.43 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011801191 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $475,456.88 | 86 |
| PY2024 | Principal investigator | $826,275.73 | 83 |
| PY2023 | Principal investigator | $2,079,973.13 | 234 |
| PY2022 | Principal investigator | $2,217,464.24 | 348 |
| PY2021 | Principal investigator | $1,780,069.51 | 284 |
| PY2020 | Principal investigator | $1,268,663.90 | 107 |
| PY2019 | Recipient | $15,750.00 | 1 |
| PY2019 | Principal investigator | $476,812.73 | 68 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Acerta Pharma LLC | $1,603.12 | 12/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543564 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,788.00 | 12/09/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327981 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,816.00 | 12/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235993949 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 11/19/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 1190329333 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327945 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327965 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327971 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327973 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327979 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327983 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328001 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328013 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328015 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328021 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328025 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $63.00 | 11/18/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328029 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 10/27/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | No dispute reported | 06/30/2026 | 1190334577 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327941 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327943 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327947 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327949 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327951 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327953 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $38.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327955 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327957 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327959 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327961 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327963 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327967 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327969 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $63.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327975 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327977 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327985 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327987 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327989 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327991 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327993 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327995 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327997 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327999 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328003 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328005 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328007 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328009 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328011 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $300.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328017 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328019 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328023 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328027 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 10/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190328031 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 09/29/2025 | Non-covered Recipient Entity Florida Cancer Specialists & Research Institute, LLC | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190336717 |
| Principal investigator 1 | BeOne Medicines Ltd. | $792.00 | 09/26/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190331859 |
| Principal investigator 1 | BeOne Medicines Ltd. | $805.00 | 09/10/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190327395 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,576.00 | 09/02/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190334203 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 08/28/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190343154 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $585.34 | 08/26/2025 | Non-covered Recipient Entity Florida Cancer Specialists - North | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235997349 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 08/12/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327933 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52,400.00 | 07/22/2025 | Non-covered Recipient Entity Florida Cancer Specialists & Research Institute, LLC | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190330113 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327929 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327931 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327935 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327937 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 07/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190327939 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 07/09/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190327357 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 06/13/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190326276 |
| Principal investigator 1 | AstraZeneca UK Limited | $18,540.00 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543562 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 05/30/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190339184 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 05/30/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190339190 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 05/21/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320768 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $270.00 | 05/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543560 |
| Principal investigator 1 | Eli Lilly and Company | $487.48 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187887474 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 05/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320754 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 05/07/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190320818 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $156.00 | 05/05/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190339186 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $44.00 | 05/05/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190339194 |
| Principal investigator 1 | BeiGene, Ltd. | $52,400.00 | 04/28/2025 | Non-covered Recipient Entity Florida Cancer Specialists & Research Institute, LLC | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190321830 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,500.00 | 04/22/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190339179 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,788.00 | 04/01/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190331321 |
| Principal investigator 1 | BeiGene, Ltd. | $805.00 | 02/14/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324220 |
| Principal investigator 1 | Celgene Corporation | $72,359.33 | 02/12/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1222305484 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 02/05/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324338 |
| Principal investigator 1 | BeiGene, Ltd. | $52,400.00 | 02/03/2025 | Non-covered Recipient Entity Florida Cancer Specialists & Research Institute, LLC | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | No dispute reported | 06/30/2026 | 1190323488 |
| Principal investigator 1 | AstraZeneca UK Limited | $7,047.50 | 01/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543556 |
| Principal investigator 1 | BeiGene, Ltd. | $2,500.00 | 01/15/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | No dispute reported | 06/30/2026 | 1190324368 |
| Principal investigator 1 | Eli Lilly and Company | $77,577.75 | 01/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187890468 |
| Principal investigator 1 | Acerta Pharma LLC | $13,416.36 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543558 |